secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-03-26T23:59:59+00:00
Accession:  0001437749-25-009399
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia reports FY2024 net loss $7.9M, cash $2.4M; CardiAMP HF data to be presented at ACC March 30
--------------------------------------------------------------------------------

- Net loss $7.9M vs $11.6M in 2023; net cash used in ops $8.0M vs $10.0M.
- Revenue $58K vs $477K; R&D expense $4.4M (down from $7.7M); SG&A $3.7M (down from $4.4M).
- CardiAMP HF trial results to be presented at ACC Late-Breaking Clinical Trials on March 30, 2025; data intended for FDA/PMDA registration.
- Completed low-dose cohort of CardiALLO (BCDA-03); DSMB review Q2 2025. First commercial Morph DNA steerable introducers available.
- Cash and cash equivalents $2.4M at year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925009399/0001437749-25-009399-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925009399/bcda20250326_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-009399

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer